Sign In   |   Register
News: Publications

New editorial on Peripheral arterial disease (PAD)

Thursday 7 December 2017   (0 Comments)
Share |

The challenge of peripheral arterial disease: how do we improve outcome?

Lower extremity peripheral arterial disease (PAD) is the tip of the atherosclerotic iceberg. Despite being common, it is typically underdiagnosed and undertreated. This is important because people with PAD often have atherosclerosis in other vascular beds and are therefore at higher risk – by 2-3 times - of cardiovascular events. And as populations age, the burden of PAD for the individual and society will undoubtedly escalate.

Reducing cardiovascular risk is a key priority. As in other high-risk groups, however, there are issues in attaining LDL cholesterol goal. Recent news from the FOURIER trial with the PCSK9 inhibitor evolocumab published in Circulation brings new hope for improving outcome in PAD. This latest commentary overviews the results and implications of these new findings.

Read the editorial on PAD by Jane Stock >>

 


Membership Software Powered by YourMembership  ::  Legal